CASPOFUNGIN
Fungal Infection
Texas Tech University Health Sciences CenterSmall moleculePhase 4 / ApprovedDormant
BBB
77/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 65/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Fungal Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Posaconazole Bochud Pierre-Yves | Phase 4 | BB |
Anidulafungin Texas Tech University Health Sciences Center | Phase 4 | BB |
Itraconazole Samsung Medical Center | Phase 4 | BB |
L-Ofloxacin Children's Oncology Group | Phase 3 | BB |
Fluconazole Bochud Pierre-Yves | Phase 3 | BB |
Voriconazole National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | B |
CYCLOSPORIN A Stanford University | Phase 2 | B |
Anti-Thymoglobulin, Rabbit Stanford University | Phase 2 | B |
Same molecule, other indications
CASPOFUNGIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →